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Abstract
Ischemic preconditioning (IPC) protects organs from ischemia reperfusion injury (IRI) through unknown mechanisms.
Effector T cell populations have been implicated in the pathogenesis of IRI, and T regulatory cells (Treg) have become a
putative therapeutic target, with suggested involvement in IPC. We explored the role of Treg in hepatic IRI and IPC in detail.
IPC significantly reduced injury following ischemia reperfusion insults. Treg were mobilized rapidly to the circulation and
liver after IRI, but IPC did not further increase Treg numbers, nor was it associated with modulation of circulating pro-
inflammatory chemokine or cytokine profiles. We used two techniques to deplete Treg from mice prior to IRI. Neither Treg
depleted FoxP3.LuciDTR mice, nor wildtyoe mice depleted of Tregs with PC61, were more susceptible to IRI compared with
controls. Despite successful enrichment of Treg in the liver, by adoptive transfer of both iTreg and nTreg or by in vivo
expansion of Treg with IL-2/anti-IL-2 complexes, no protection against IRI was observed.We have explored the role of Treg
in IRI and IPC using a variety of techniques to deplete and enrich them within both the liver and systemically. This work
represents an important negative finding that Treg are not implicated in IPC and are unlikely to have translational potential
in hepatic IRI.
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Introduction
Ischemia reperfusion injury (IRI) is the cause of considerable
morbidity and mortality across a wide range of common diseases.
In liver resection surgery, ischemic insults cause post-operative
transaminasemia and failure of synthetic function. In liver
transplantation, IRI causes a spectrum of graft dysfunction,
ranging from biochemical abnormalities through to primary
non-function of the transplanted organ [1].
Ischemic preconditioning (IPC) is a manoeuvre in which brief
interruption, then reinstatement of an organ’s blood supply
protects that organ from subsequent injury. IPC has been shown
to protect the liver from subsequent IRI in animals and humans
[2,3]; its mechanism of action has yet to be fully elucidated.
In recent years, IRI has been thought of as an example of sterile
inflammation, and the contribution of lymphocytes has been
examined extensively. A transient T cell influx has been described,
occurring during the first few hours of reperfusion, and resolving
by 24 hours [4,5]. Nude [6,7], RAG1 knockout [8], SCID [9],
TCRab2/2 [10], and CD42/2 animals [6] have all been
shown to be protected from IRI. Experiments in which the
protected phenotype of nude mice has been reversed by adoptive
transfer of CD4+, but not CD8+lymphocytes, have been published
in both renal [6] and liver ischemia [11] models. Inhibition of
lymphocyte chemotaxis through manipulation of the sphingosine-
1-phosphate (S1P) pathway has also been used to ameliorate IRI
[5,12,13].
Since this data suggests that effector T cells contribute to IRI,
CD4+CD25+FoxP3+T regulatory cells (Treg) have become a
putative therapeutic target. Treg depletion/reconstitution exper-
iments in renal ischemia [8,14], and pharmacotherapies designed
to enhance Treg recruitment [15] have suggested a protective role
for Treg, while adoptive transfer of induced Treg showed
therapeutic potential in models of renal [14] and hepatic ischemia
[16,17]. In addition to experiments, which have directly examined
the potential of Treg as a cellular therapy, several molecules and
pathways linked with Treg activity have also been associated with
IPC. IL-10 was shown to be over-expressed in renal [14] and
hepatic IPC, which conversely was abolished by IL-10 neutralizing
antibodies [18]. Receptor mediated purinergic signalling with
adenosine has long been implicated in protection induced by IPC
[19]. Degradation of interstitial ATP to adenosine is catalysed by
the ectonucleotidase CD39, which is expressed by Treg and
implicated in their suppressive function [20,21]. CD392/2
animals are susceptible to hepatic ischemic injury, whereas
administration of soluble CD39 attenuated hepatic injury:
furthermore, CD39 was shown to be induced by IPC [22].
The potential of immunomodulation as a therapeutic strategy
for hepatic IRI was supported by our previous work, in which we
showed that hemeoxygenase-1 (HO-1) protected the liver from
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ischemic injury by modulation of antigen presenting cell (APC)
differentiation to an anti-inflammatory phenotype [23]. Subse-
quent work by others showed that FoxP3+Treg mediated immune
suppression to requires APC HO-1 [24].
Here we have used a range of approaches to study the
contribution of Treg to IPC in vivo, and to establish whether this
cell type is likely to have translational potential in the context of
hepatic ischemia. We demonstrate that in our model, Treg do not
modulate ischemic injury, and are unlikely to contribute to IPC.
Materials and Methods
Ethics Statement
All procedures and animal care were approved by the
University of Edinburgh Ethical Review Committee and per-
formed in accordance with UK Home Office licensing regulations
(Animal Scientific Procedures Act 1986).
Animals, Surgical Models, and Injury Assessment
C57 BL/6J animals with insertion of a BAC containing a
cassette encoding enhanced GFP (eGFP), the human DTR, and
CBGr99 luciferase within exon 3 of the FoxP3 gene (FoxP3.Lu-
ciDTR) mice were made available by G. Hammerling, Heidelberg
[25]. Foxp3 GFP reporter mice on the C57BL/6J background
were provided by Dr. A. Rudensky, Seattle [26].
IRI animals underwent surgical occlusion of the portal pedicle
(hepatic artery and portal vein) supplying the left hepatic lobe for
50 minutes under isoflurane anaesthesia as described by previously
[23,27,28]. IPC mice, underwent portal pedicle occlusion for 15
minutes followed by 15 minutes reperfusion prior to the 50 minute
ischemic insult. Core temperature was maintained at 36uC
throughout. Animals were culled at various times post-operatively.
All experiments were internally controlled.
Severity of ischemic injury was assessed by measurement of
serum ALT utilising a commercial kit (Alpha Laboratories Ltd.,
Eastleigh, UK) adapted for use on a Cobas Fara centrifugal
analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK).
Histological injury was evaluated on haematoxylin and eosin
stained sections at 100x magnification on a bright field micro-
scope. Percentage area necrosis was estimated on representative
sections.
Reagents
Diphtheria toxin (DT) 25 ng/g (Sigma-Aldrich, Poole, UK) was
used to deplete FoxP3 Treg in FoxP3.LuciDTR animals 24 hr
prior to surgery. DT treated wildtype littermates served as
controls. Adequate depletion of Treg was confirmed by loss of
CD4+GFP (FoxP3)+cells from tail vein blood samples prior to
surgery.
Wildtype C57BL/6J animals underwent Treg depletion using
PC61, a CD25 depleting antibody (Bio6Cell, New Hampshire,
USA), 7 and 2 days pre-operatively. CD25+and FoxP3+depletion
was confirmed by flow cytometry of splenocytes in post-operative
animals.
IL-2/anti-IL2 complexes were prepared using Garvan Institute
laboratory protocols as described previously [29]. Mice received
pre-incubated complexes containing 1 ug IL-2 (Peprotech,
London, UK) and 5 ug anti-IL-2 Ab (clone JES6/A12,
eBioscience, Hatfield, UK) on three consecutive days 72, 48,
and 24 hours prior to surgery.
Flow Cytometry
Hepatic lymphocytes were prepared from liver samples by tissue
disaggregation using Miltenyi Gentlemacs (Miltenyi Biotec, UK),
followed by digestion by Collagenase D (Roche, Burgess Hill, UK),
and passage through a 70 mm filter. Cells were layered onto
lympholyte M (Cedarlane, Ontario, Canada) for density centrifu-
gation and separation of lymphocytes.
Splenocytes were preparared by passage through a 40 mm filter
followed by red cell lysis with ammonium chloride buffer (Sigma
Aldrich, Dorset, UK). Blood was collected from tail vein or cardiac
puncture into EDTA buffer. Erythrocytes were lyzed with
ammonium chloride buffer.
Samples containing approximately 106 cells were stained as
follows. Cell surface antigens were stained with antibodies to
CD4+AF700 (Caltag Medsystems, Buckingham UK) and
CD62L PE for 20 minutes at room temperature at dilutions
of 1:200 (CD4) and 1:100 (others). Intracellular staining of
FoxP3 or isotype control (eBioscience, Hatfield, UK), utilized a
fixation/permeabilization kit (eBioscience) according to the
manufacturer’s instructions. Antibodies were incubated at
1:100 dilution for 30 minutes.
Flow cytometry was performed using a LSR Fortessa cytometer
(Becton Dickinson UK), gated on lymphocytes identified by
forward and side scatter characteristics.
Immunohistochemistry and Cell Counting
Tissue samples were formalin fixed prior to paraffin
embedding. Sections were stained with rabbit anti mouse
CD3 (Sigma-Aldrich, Poole, Dorset, UK) at 1:1000 dilution.
Staining was detected with diaminobenzidine with haematoxylin
counterstaining. Numbers of stained cells were counted on 400x
fields selected at random by isotropic uniform random sampling
(Image pro-plus software, Media Cybernetics Inc, CA, USA)
using a Zeiss Axis A1 (Carl Zeiss Ltd, Cambridge, UK)
stereology microscope.
Measurement of Circulating Cytokines
Serum samples were analysed for IP-10, GM-CSF, IL-1a, IL-
1b, IL-2, IL-6, IL-10, IL-17, IL-17F, CXCL-1/KC, MIP-1a,
MIP-1b and IFNc using a multiplex FlowCytomix kit
(eBioscience) according to the manufacturer’s instructions. Data
was collected using an LSR Fortessa cytometer (Becton Dickinson,
UK) and analysed with Flowcytomix Pro v2.4 software
(eBioscience).
Preparation of Cells for Adoptive Transfer
iTreg were generated by Miltenyi Macs negative selection of
CD4 cells from FoxP3 GFP mouse spleens (Miltenyi Biotec, UK).
CD4+CD62L high GFP- naı¨ve T cells were subsequently purified
by FACS sorting. These were plated into anti-CD3/anti-CD28
coated plates in the presence of 5 ng/ml TGFb and 100 U/ml IL-
2 and cultured for 5 days [30]. iTreg were purified using FACS
sorting for CD4+GFP+prior to adoptive transfer of 1–2 million
cells 24 hours prior to ischemic insult. Successful engraftment of
donor cells was confirmed by flow cytometry of recipient blood,
liver and spleen.
nTreg were obtained by Miltenyi Macs negative selection of
CD4 cells from FoxP3 GFP mouse spleens, followed by FACS
sorting. FoxP3 expression was previously shown to be more
stable in CD4+CD62L high FoxP3+cells [31], therefore this
subgroup was selected for ex-vivo expansion. Around 2–36105
nTreg were recovered from each donor mouse, which
underwent ex vivo expansion in the presence of Dynal CD3/
CD28 activation beads (Life Technologies, Paisley, UK) and
high dose (2000U/ml) IL-2 in order to produce around 10–20
fold expansion at 21 days.
Hepatic IPC Is Independent of Treg
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Statistical Analysis
Data were collected in Microsoft Excel for Mac and analysed
using Prism version 5 (Graphpad, San Diego, USA). Data are
presented as mean+/2 standard error. Comparison of means was
with 2 tailed t test or ANOVA as appropriate.
Results
Treg Mobilization during Reperfusion
IPC protected the liver from injury both in terms of ALT release
and histological injury score measured at 24 hours [Figure 1a,b].
Early reperfusion was accompanied by a significant mobilization
of FoxP3+T regs into the circulation, rising to between 10 and
15% of circulating CD4+cells at 3 hours, and remaining elevated
at later time points [Figure 1c]. In turn, the liver accumulated T
regs, rising to 5–10% of hepatic CD4+cells at 24 hours [Figure 1d].
Total numbers of CD3+lymphocytes detected on immunohisto-
chemistry was stable throughout reperfusion [Figure 1e].
Importantly, despite the significant protection from injury
offered by IPC, numbers of Treg in the circulation and
enrichment within the liver was similar between IRI and IPC
mice [Figure 1c, d]. Thus enrichment with Treg was not
associated with a protected phenotype.
To further evaluate whether IPC might be associated with Treg
activity, serum chemokine and cytokine profiles were compared
between animals subject to IRI and IPC. Cytokines IL-1a, IL-1b,
IL-2, IFNc, IL-17 and IL-17F, and IL-10 were not detected in the
serum of either IRI or IPC animals. There were rises in CXCL-
10/IP-10 [Figure 1f], KC/CXCL-1 [Figure 1g], IL-6 [Figure 1h]
and GM-CSF [Figure 1i].
Apart from a small difference in levels of serum CXCL-10/IP-
10, and a trend towards lower KC/CXCL-1 in IPC mice
(p = 0.06), chemokine and cytokine profiles did not significantly
differ between IRI and IPC groups [Figure 1f, g, h, i]. Specifically,
IPC was not associated with significant reductions in pro-
inflammatory cytokines or an excess of IL-10, which may have
implicated a role for Treg.
Effect of T Regulatory Cell Depletion
If Treg were responsible for modulating ischemic injury, then
Treg deficient animals would be more susceptible to injury. To test
this hypothesis, we depleted animals of Treg using two comple-
mentary approaches.
Foxp3.LuciDTR mice or wildtype littermates received diph-
theria toxin 25 ng/g 24 hours prior to IRI. Loss of
CD4+FoxP3+cells, from blood [Figure 2c,d], spleen [Figure 2e],
Figure 1. Treg mobilization during reperfusion is not enhanced by IPC. Mice (n = 5–8 per group) were subjected to ischemia reperfusion
injury with or without ischemic preconditioning and killed at 3 or 24 hours. Ischemic preconditioning protected the liver from injury both in terms of
ALT release [a] and histological injury score [b] measured at 24 hours. CD4+FoxP3+cells were mobilized into the circulation during reperfusion [c].
Hepatic CD4+FoxP3+cells increased over the same time period [d]. Total CD3+lymphocytes were stable throughout reperfusion [e]. FlowCytomix was
used to profile circulating chemo/cytokines. Rises were detected in CXCL-10/IP-10 [f], CXCL-1/KC [g], IL-6 [h] and GMCSF [i]. Other analytes (IL-1a, IL-
1b, IL-2, IFNc, IL-17 and IL-17F, and the Treg cytokine IL-10) were not detected.
doi:10.1371/journal.pone.0049647.g001
Figure 2. Treg depletion in the FoxP3.LuciDTR mouse does not increase susceptibility to IRI. FoxP3.LuciDTR mice or wildtype control
(n = 5–10 per group) received 25 ng/g DT 24 hours prior to ischemic insult. ALT release [a] and histological injury score [b] did not differ between
groups. DT treatment of DTR animals effected almost total depletion of Treg from the circulation [c,d], spleen [e] and liver [f].
doi:10.1371/journal.pone.0049647.g002
Hepatic IPC Is Independent of Treg
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and liver [Figure 2f] was profound. Despite this, injury severity
was equal between Treg depleted Foxp3.LuciDTR and DT
treated Treg intact wildtype littermate control animals at 24
hours of reperfusion [Figure 2a, b].
Since DT treatment is toxic, and exacerbated IRI in these
experiments, we verified the absence of Treg mediated protection
using antibody depletion. Mice received two doses of the
monoclonal anti CD25 antibody PC61 or PBS control 7 days
and 2 days prior to surgery, as described previously by our
laboratory [32]. During protocol optimization, this regimen
reduced numbers of CD25+cells to around one third of their
original number, and approximately halved the proportion of
splenic FoxP3+CD4+cells [Figure 3c,d]. PC61 Treg depleted mice
were no more susceptible to IRI in terms of ALT or histological
injury score than Treg intact animals [Figure 3a,b].
FlowCytomix was used to measure cytokine and chemokine
levels in serum from animals undergoing antibody mediated Treg
depletion prior to ischemic insult. No differences were detected
between Treg depleted and vehicle treated animals [Figure 3e, f, g,
h], specifically, the relative absence of Treg did not result in
Figure 3. Treg antibody depletion does not increase susceptibility to IRI. Wildtype mice received the CD25 depleting antibody pc61 7 and 2
days or PBS (n = 5–8 per group) prior to ischemia reperfusion injury. Injury severity was no different between Treg intact and Treg depleted animals in
terms of ALT [a] or histological injury score [b]. PC61 treatment resulted in significant depletion of CD4+CD25+[c] and CD4+FoxP3+[d] cells.
FlowCytomix was used to profile circulating chemo/cytokines. No differences were detected in post-operative rises in CXCL-10/IP-10 [e], KC/CXCL-1
[f], IL-6 [g] and GM-CSF [h] between Treg intact and depleted animals. Other analytes (IL-1a, IL-1b, IL-2, IFNc, IL-17 and IL-17F, and IL-10) were not
detected.
doi:10.1371/journal.pone.0049647.g003
Hepatic IPC Is Independent of Treg
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elevated levels of circulating pro-inflammatory cytokines at 24
hours of reperfusion. Cytokines IL-1a, IL-1b, IL-2, IFNc, IL-17
and IL-17F, and IL-10 were not detected in the serum of Treg
intact or Treg depleted animals at all [data not shown]. Post-
operative rises in CXCL-10/IP-10 [Figure 3e], KC/CXCL-1
[Figure 3f], IL-6 [Figure 3g] and GM-CSF [Figure 3h] did not
differ between groups. Of note, secretion of pro-inflammatory
chemokines and cytokines was not exacerbated in Treg depleted
animals.
The lack of increased susceptibility of Treg depleted mice to
ischemic injury suggests that Treg do not have a physiological role
in modulating injury, and are unlikely to be responsible for the
protected phenotype observed in IPC.
Testing the Therapeutic Potential of Transferred or
Expanded Pre-activated Treg
If Treg were capable of ameliorating ischemic injury, expansion
of Treg numbers might be protective. To test this hypothesis we
supplemented animals with additional activated Treg using
techniques shown to protect animals from other inflammatory
pathologies within our laboratory.
Activated FoxP3 GFP iTreg were generated in vitro using
techniques previously published by our laboratory [30], and
purified to <99% by FACS sorting, before adoptive transfer of 1–
2 million cells [Figure 4a, b, c, d]. 24 hours later, animals were
subjected to hepatic ischemic insult. Successful engraftment of
donor cells was confirmed by flow cytometry of recipient spleen
[Figure 4e] and liver [Figure 4f]. Cells were prepared and
transferred using procedures and reagents shown to confer
protection in other models in reports from our laboratory [30].
No difference in injury severity was observed between recipients of
adoptively transferred iTreg and control animals [Figure 4g].
Since previous reports have shown iTreg to produce IFNc when
stimulated [30], and FoxP3 GFP reporter iTreg have been shown
to exhibit reduced stability of FoxP3 expression and reduced
suppressive ability [33], experiments were repeated using adop-
tively transferred nTreg.
1–2 million cells were transferred into recipient mice prior to
ischemic injury [Figure 5a, b, c]. Despite engraftment of nTreg
[Figure 5d,e], mice were not protected from ischemic injury in
terms of ALT at 3 hours of reperfusion [Figure 5f].
A possible explanation of the failure of adoptive transfer
experiments to protect animals from ischemic injury was that
insufficient Treg had been transferred to ameliorate injury. IL-2/
anti-IL-2 complexes have been shown to induce Treg expansion,
protecting experimental models from airway inflammation [34],
experimental autoimmune encephalomyelitis (EAE) [29], and
conferring long term tolerance to pancreatic allografts [29]. Prior
to ischemia reperfusion insults, animals received three consecutive
daily injections of IL-2/anti-IL-2 complexes resulting in substan-
tial Treg expansion in spleen [Figure 6a], blood [Figure 6b] and
liver [Figure 6c].
Despite a two to threefold expansion in Treg, including in the
liver, animals were not protected from injury in terms of ALT
release or histological injury score at 24 hours of reperfusion
[Figure 6d,e].
Figure 4. Adoptive transfer of pre-activated iTreg does not protect animals from IRI. iTreg were generated in vitro from sorted CD62L
high, FoxP3- naı¨ve T cells cultured in the presence of TGFb and IL-2 for 5 days before flow sorting to maximize purity [a-d]. Successful transfer was
confirmed by detection of FoxP3 GFP+cells in spleen [e] and liver [f]. No difference was detected in injury severity between iTreg supplemented and
PBS treated control animals at 3 or 24 hours of reperfusion (n = 4–5 per group) [g].
doi:10.1371/journal.pone.0049647.g004
Hepatic IPC Is Independent of Treg
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Serum cytokine/chemokine profiles showed increased levels of
IL-2 in keeping with exogenous administration [Figure 6f].
Interestingly, CXCL-10/IP-10 was elevated in complex treated
animals compared with PBS treated controls [Figure 6g], as was
IL-6 [Figure 6h]. KC/CXCL-1 [Figure 6i], and GM-CSF
[Figure 6j] did not differ between groups. Other analytes (IL-1a,
IL-1b, IL-10, IL-17, IL-17F, IFNc, MIP-1a) were not detected in
either group.
Discussion
These experiments, which employed a range of strategies of
Treg supplementation/expansion previously shown to ameliorate
other inflammatory disorders, demonstrate that Treg are unlikely
to represent a useful therapeutic target in amelioration of hepatic
IRI.
We have shown a rapid mobilization of Treg into the circulation
and accumulation in the liver during the first 24 hours of
reperfusion. This mobilization and accumulation was not exag-
gerated by IPC, and did not inversely correlate with severity of
ischemic injury, as would have been predicted had they had a
significant role in injury modulation.
Profound depletion of Treg in the FoxP3 LuciDTR mouse did
not affect injury compared with appropriate DT treated control
animals. Antibody depletion of CD25+cells (which led to partial
loss of FoxP3+Treg) also did not adversely affect outcome of
ischemia reperfusion insults. If Treg were protective, injury would
have been more severe in Treg deficient animals than Treg intact
controls.
Conversely, if Treg were implicated in IPC, supplementation or
expansion of these cells would be expected to recapitulate the
protected preconditioned phenotype. We employed three putative
therapeutic strategies of either Treg transfer or expansion, in
attempts to ameliorate injury. Pre-activated iTreg have previously
been used in our laboratory to ameliorate experimental autoim-
mune encephalomyelitis (EAE) [30]. In our ischemia model, we
were unable to demonstrate protection. We hypothesized that a
protective effect might be undermined by potentially pathological
IFNc production by iTreg [30]. We also noted recent data
demonstrating impaired suppressive capability and FoxP3 stability
in FoxP3 GFP iTreg [33]. Thus, we undertook further experi-
ments using transferred ex vivo expanded nTreg [31] which again
did not protect the liver from ischemic injury.
A limitation of adoptive transfer experiments is their inability to
significantly expand circulating or tissue Treg numbers. We
transferred similar numbers of iTreg and nTreg to those shown to
protect animals from other inflammatory disorders, and trans-
ferred cells which were pre-activated, increasing their likely
suppressive potency. Nonetheless, 1–2 million Treg remains a
small proportion of the total number within the host mouse, and
donor cells were detected in the liver and spleen at around 0.5%
CD4+cells.
Figure 5. Adoptive transfer of pre-activated nTreg does not protect animals from IRI. nTreg were obtained from FoxP3 GFP mouse
spleens by flow sorting followed by expansion in vitro for 21 days and further flow-sorting for purity [a–c]. Flow cytometry of spleen and liver
confirmed successful transfer [d,e]. There was no difference in injury severity between nTreg supplemented and control animals at 3 hours of
reperfusion (n = 4 per group) [f].
doi:10.1371/journal.pone.0049647.g005
Hepatic IPC Is Independent of Treg
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To address this issue, we utilised IL-2/anti IL-2 complexes,
which have been shown to ameliorate airway inflammation [34],
and EAE, as well as inducing long term tolerance to transplanted
pancreatic islets [29]. In common with previously published
reports, this technique produced major Treg expansion in the
spleen, circulation and liver. Despite 25% of hepatic CD4+cells
being FoxP3+, the ischemic preconditioned phenotype was not
recapitulated by in vivo Treg expansion.
It would be possible to ascribe a lack of protective effect in Treg
transferred or expanded animals to those cells’ polyclonal TCR
repertoire. Previous work using transgenic TCR restricted models
highlighted that Treg recognising a disease-relevant autoantigen
are more effective than polyclonal Treg in prevention of EAE [31].
In contrast, ischemic injury is likely to result in unveiling of a wide
range of antigens as the contents of lysing cells are ‘‘spilt’’ into the
interstitium. As such, TCR restricted models are not only
unavailable, but they are also unlikely to be therapeutically
relevant in the context of IRI.
In these experiments, we have used a number of complemen-
tary approaches to establish whether Treg have a role in
modulating hepatic IRI, and have found no data to support this
hypothesis. Other published Treg depletion experiments have
had mixed results using the PC61 anti-CD25 antibody, with
some showing increased susceptibility [8,14,35], and others
unable to demonstrate an effect [15,36] in IRI models. Results
of Treg supplementation experiments from other laboratories
contrast with our own data. Transfer of iTreg cells into mice [16]
and rats [17] have been shown by others to be protective against
hepatic IRI. RAG1 knockout mice, which underwent reconsti-
tution with FoxP32/2 lymphocytes were highly vulnerable to
ischemic injury compared with recipients of wildtype lympho-
cytes [8]. In a study of late phase preconditioning (in which the
preconditioning insult occurred 7 days prior to index ischemia),
the same group showed that Treg accumulated during resolution
of injury, and that these partially reduced the severity of
subsequent ischemic insults [14].
Figure 6. In vivo expansion of Treg does not protect animals from IRI. Mice received IL-2/JES6-A12 complexes or PBS for three consecutive
days prior to hepatic ischemia reperfusion insults (n = 8 per group). Animals were culled at 24 hours of reperfusion, and tissues analysed for Treg
frequency. There was significant expansion of splenic [a], circulating [b] and hepatic [c] Treg. Injury severity was similar between Treg expanded and
control animals, in terms of ALT and histological injury [d,e]. FlowCytomix was used to profile circulating chemo/cytokines. Levels of IL-2 [f], CXCL-10/
IP-10 [g] and IL-6 [h] were elevated. Rises in KC/CXCL-1 [i], and GM-CSF [j] did not differ between groups. Other analytes (IL-1a, IL-1b, IL-10, IL-17, IL-
17F, IFNc, MIP-1a) were not detected.
doi:10.1371/journal.pone.0049647.g006
Hepatic IPC Is Independent of Treg
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The work presented here demonstrates an important negative
finding, contrary to our original hypothesis, that Treg are unlikely
to be responsible for IPC. Clearly this cell type represents an
important therapeutic target for the treatment of a wide range of
immune mediated disorders, but it is unlikely to be of clinical value
in the treatment of ischemia reperfusion injury.
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